Anthony Rosenberg

Anthony Rosenberg General Information

Biography

Mr. Tony Rosenberg served as Senior Advisor at Kurma Partners. Mr. Rosenberg serves as Board Member at Cullinan Mica. He served as Executive Partner at MPM Capital. Prior to joining MPM, he served as Global Head, M&A and Licensing (Corporate) for Novartis, based in Basel, Switzerland. In this role he oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. He also served as Board Member at iOmx Therapeutics. He is a Board member at Cullinan Oncology, Radius and a former board member at Idenix, both MPM portfolio companies. He joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions in sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, he was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. he has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.